Destiny Pharma targets growth as anti-infection treatments return to prominence

0
23

() said its partner in China is to launch a new programme aimed at delivering a new product using Destiny’s XF-73 to target the prevention and treatment of superficial skin infections caused by bacteria.

() Ltd (CMS), the AIM-listed company’s regional partner and also an investor with a 5.76% stake, is establishing a programme in China to focus on developing a novel product in the local regulatory environment.

CMS will lead, manage and fund the programme, with Destiny contributing scientific advice as required through a steering committee to the expert dermatology team at CMS.

Destiny Pharma noted that CMS already has a portfolio of dermatology assets and therefore an expert understanding of the market and its requirements through its existing sales and marketing infrastructure.

LEAVE A REPLY

Please enter your comment!
Please enter your name here